GlassScriptPhysician profile
Jennifer L Kottler
NPI 1740975366
$1,791.08
in general payments reported to CMS, 2019-2025
16 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $158 · 2024: $496 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $329.22 | 2023-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $262.31 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $248.80 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $226.03 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $221.16 | 2024-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.26 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $70.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $62.56 | 2025 | Cobenfy |
| Corium, LLC | $60.40 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $57.10 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $42.39 | 2024-2025 | Auvelity |
| Indivior INC. | $39.60 | 2024 | Sublocade |
| Shield Therapeutics INC | $25.70 | 2023 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $24.68 | 2024 | Flumist Quadrivalent |
| Supernus Pharmaceuticals, INC. | $22.54 | 2024 | Qelbree |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $19.85 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kottler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.